Investors at Skye Bioscience, Inc. Can Join Ongoing Securities Fraud Class Action

Investors Encouraged to Participate in Skye Bioscience Class Action

Investors of Skye Bioscience, Inc. (NASDAQ: SKYE) who purchased securities between November 4, 2024, and October 3, 2025, have an important notice from the Rosen Law Firm regarding potential legal recourse for alleged securities fraud. With a lead plaintiff deadline set for January 16, 2026, eligible investors are reminded of their opportunity to be part of a class action lawsuit that seeks justice and potential compensation without upfront costs.

What You Need to Know

The Rosen Law Firm, renowned for pioneering investor rights, has filed a class action lawsuit on behalf of affected purchasers. If you bought shares of Skye Bioscience during the specified timeframe, you may be eligible to receive compensation for the alleged fraud committed by the company's executives and board members. Importantly, you may pursue this route without facing out-of-pocket expenses due to the firm’s contingency fee arrangement.

The Allegations

According to the court filings, the defendants at Skye Bioscience purportedly made materially false and misleading statements about the company's business operations, particularly regarding their primary product, nimacimab. The lawsuit claims that the efficacy of nimacimab was overstated, leading investors to believe in its clinical and commercial potential that did not align with reality. This misrepresentation has supposedly caused significant financial losses for the investors when the truth was eventually revealed to the marketplace.

Next Steps for Investors

Eligible investors are advised to take action promptly. You can join the Skye Bioscience class action by visiting Rosen Law Firm's submission page or by contacting Phillip Kim, Esq. at (866) 767-3653 for further instructions.

If you wish to take a lead role in the case as a lead plaintiff, you must file a motion before the outlined deadline. A lead plaintiff functions as a representative for other class members and plays a crucial role in guiding the case proceedings.

Importance of Choosing the Right Counsel

When dealing with securities litigation, it’s essential to select experienced legal counsel. The Rosen Law Firm emphasizes that many firms simply act as intermediaries instead of genuinely advocating for investors' rights. Rosen Law Firm specializes in securities class actions, boasting a notable history, including achieving the largest settlements against several companies. Their track record and recognition in the field lend confidence to investors seeking to navigate this complex legal terrain.

Final Thoughts

Investors affected by the actions of Skye Bioscience are encouraged to consider their options and act swiftly. The Rosen Law Firm is here to assist you in understanding your rights and potential compensation. Remember, participating in a class action doesn’t require you to personally manage the case; rather, the appointed lead plaintiff will handle most of the proceedings. Given the upcoming deadline, now is the time to act if you meet the qualifications. For more updates, follow the Rosen Law Firm’s social media or contact them directly through their website.

Contact Information

For additional queries or assistance, you can reach out to:
Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Phone: (212) 686-1060
Toll-Free: (866) 767-3653
Website